Advanced Cell Technology

ACT begins trials for macular dystrophy treatment

Friday, July 15, 2011 10:30 AM

Advanced Cell Technology announced the dosing of the first patients in each of its two phase I/II clinical trials for Stargardt's macular dystrophy and dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patients were treated by Steven Schwartz, M.D., at the David Geffen School of Medicine at UCLA. Robert Lanza, M.D., chief scientific officer of ACT, attended the procedures. Both patients successfully underwent the outpatient transplantation surgeries and are recovering uneventfully.

More... »


ACT and Oregon Health & Science University collaborate in SMD trials

Monday, May 16, 2011 01:01 PM

Advanced Cell Technology (ACT), a company involved in regenerative medicine, reports that the Casey Eye Institute (CEI) at Oregon Health & Science University (OHSU) has received institutional review board (IRB) approval to be a site for its phase I/II human clinical trial for Stargardt's Macular Dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

More... »


ACT CEO Gary Rabin to present at World Stem Cells & Regenerative Medicine Congress

Thursday, May 5, 2011 12:08 PM

Advanced Cell Technology, a company involved in regenerative medicine, report that its interim chairman and CEO Gary Rabin will be presenting at the World Stem Cells & Regenerative Medicine Congress, May 9-11, in London.

More... »

Advanced Cell Technology receives IRB approval for SMD/AMD studies at UCLA

Friday, April 29, 2011 10:57 AM

Massachusetts-based Advanced Cell Technology, a biotechnology company focused on developing regenerative medicine, reports that the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA) has received institutional review board (IRB) approval to be a site for its phase I/II human clinical trials for Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.